Pascal is an EIR and President/Chief Scientific Officer of a Stealth NewCo. In his nearly two decades in Pharma and Biotech, Pascal has developed a passion for the discovery of innovative and often cryptic ways to modulate protein function and signaling pathways, developing small and not-so-small molecules into highly effective medicines. Prior to joining Atlas Venture, Pascal was CSO and Head of Early Research at Relay Therapeutics. In this role, Pascal helped build and deploy the drug discovery engine across a wide array of targets and modalities, leading to the generation of several clinical stage molecules. Prior to Relay Therapeutics, Pascal took on roles of increasing responsibility at Novartis Biomedical Research, where he led the Molecular Pharmacology and Biological Chemistry Department in Oncology. Pascal completed his postdoctoral studies at Harvard Medical School, where he researched natural product biosynthetic pathways and small molecule regulation of protein function. He received his Ph.D. from the University of British Columbia, where he studied enzyme regulation and engineering, and obtained a B.Sc. in Biochemistry from Laval University.